Shylicine™, Mikrovillus İnklüzyon Hastalığına (MVID) sahip hastaların TPN ihtiyacını ortadan kaldırma hedefiyle geliştirilmiş bir kokteyl ilaçtır.
Shylicine™, MVID’nin neden olduğu emme ve salgılama dengesizliğini eski haline getirir ve bağırsak mukozasının işlevini ve görünüşünü onarır.
July 25, 2018 – Hamden, Connecticut
(VRI) is pleased to announce the launch of its educational website focused on microvillus inclusion disease (MVID) translated into the Turkish language. The website explains the mechanism of MVID, provides targeted resources both for doctors and caregivers, and publishes new scientific research and other pertinent news and information related to this rare genetic disease.
June 28, 2018 – Hamden, Connecticut
Vanessa Research. (VRI), has announced the launch of a new educational video ( link ) on microvillus inclusion disease (MVID) – a rare, genetic intestinal disease that causes severe diarrhea in young babies, and it is resistant to treatment.
September 15, 2017 – Hamden, Connecticut
We have taken many steps this summer to getting Shylicine approved for use in treating microvillus inclusion disease, a rare pediatric disorder that causes chronic diarrhea. Our goal with this oral anti-diarrheal treatment is to restore intestinal function so patients can eat and drink normally.